HIV vaccine - United Biomedical

Drug Profile

HIV vaccine - United Biomedical

Alternative Names: HIV synthetic peptide vaccine - United Biomedical; p2249f

Latest Information Update: 23 Sep 2016

Price : $50

At a glance

  • Originator United Biomedical
  • Developer Nonindustrial source; United Biomedical
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 23 Sep 2016 Preclinical development is ongoing in USA (United Biomedical pipeline, September 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-infections in USA (Parenteral, Injection)
  • 19 Jul 2001 A phase I trial of the V3 peptide vaccine has been added to the adverse events and Viral Infections immunogenicity sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top